Form 4 for DYN Dyne Therapeutics, Inc.
Accepted 2023-06-12 00:00:00 ET · period of report 2023-06-08 · accession 0001209191-23-036544 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| DM | 2023-06-12 | 2023-06-08 | DYN | Brumm Joshua T | See Remarks, Dir | G - Gift | $0.00 | -21.8K | 302.5K | -7% | $0 |
| DM | 2023-06-12 | 2023-06-08+ | DYN | Brumm Joshua T | See Remarks, Dir | M - OptEx | $1.03 | +278.0K | 441.1K | +170% | +$286.4K |
| DM | 2023-06-12 | 2023-06-08+ | DYN | Brumm Joshua T | See Remarks, Dir | S - Sale+OE | $12.90 | -325.3K | 269.8K | -55% | -$4.20M |
| DM | 2023-06-12 | 2023-06-08+ | DYN | Brumm Joshua T | See Remarks, Dir | M - OptEx | $0.00 | -278.0K | 69.7K | -80% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2023-06-08 | G | D | 1,800 | $0.00 | 300,683 | D | — | — | |
| 2 | Common | Common Stock | 2023-06-08 | M | A | 30,088 | $1.03 | 330,771 | D | — | — | |
| 3 | Common | Common Stock | 2023-06-08 | S | D | 46,811 | $13.15 | 283,960 | D | — | — | (F2) The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices within the range of $13.10 to $13.23, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (1) and (2) of this Form 4. |
| 4 | Common | Common Stock | 2023-06-12 | S | D | 187,748 | $12.61 | 253,383 | D | — | — | (F5) The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices within the range of $12.18 to $13.14, inclusive. |
| 5 | Common | Common Stock | 2023-06-09 | M | A | 76,582 | $1.03 | 346,353 | D | — | — | |
| 6 | Common | Common Stock | 2023-06-09 | S | D | 76,582 | $13.34 | 269,771 | D | — | — | (F4) The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices within the range of $13.00 to $13.64, inclusive. |
| 7 | Common | Common Stock | 2023-06-12 | M | A | 171,360 | $1.03 | 441,131 | D | — | — | |
| 8 | Common | Common Stock | 2023-06-08 | G | D | 20,000 | $0.00 | 302,483 | D | — | — | |
| 9 | Common | Common Stock | 2023-06-08 | S | D | 14,189 | $13.47 | 269,771 | D | — | — | (F3) The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices within the range of $13.24 to $14.22, inclusive. |
| 10 | Derivative | Stock Option (right to buy) | 2023-06-08 | M | D | 30,088 | $0.00 | 317,661 | D | $1.03 · — to 2030-01-05 | 30,088 Common Stock | (F6) The option was granted on January 6, 2020. The shares underlying the option vest over four years, with 25% of the shares vesting on October 12, 2020 and the remaining shares vesting in equal quarterly installments thereafter. |
| 11 | Derivative | Stock Option (right to buy) | 2023-06-09 | M | D | 76,582 | $0.00 | 241,079 | D | $1.03 · — to 2030-01-05 | 76,582 Common Stock | (F6) The option was granted on January 6, 2020. The shares underlying the option vest over four years, with 25% of the shares vesting on October 12, 2020 and the remaining shares vesting in equal quarterly installments thereafter. |
| 12 | Derivative | Stock Option (right to buy) | 2023-06-12 | M | D | 171,360 | $0.00 | 69,719 | D | $1.03 · — to 2023-01-05 | 171,360 Common Stock | (F6) The option was granted on January 6, 2020. The shares underlying the option vest over four years, with 25% of the shares vesting on October 12, 2020 and the remaining shares vesting in equal quarterly installments thereafter. |